Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.
Eur J Nucl Med Mol Imaging
; 46(1): 8-10, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30310953
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.
Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues.
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.
Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.
Current application and future perspectives of PSMA PET imaging in prostate cancer.